News

BMJ2d
Low-dose glucocorticoids plus rituximab versus high-dose glucocorticoids plus rituximab for remission induction in ANCA-associated vasculitis (LoVAS): protocol for a ...
Introduction Antineutrophil cytoplasm antibody-associated vasculitis (AAV) is a form of systemic vasculitis. The current standard induction therapy with the combination of high-dose glucocorticoids ...
BMJ7d
Prospective open-label trial with rituximab in patients with chronic inflammatory demyelinating polyradiculoneuropathy not responding to conventional immune therapies
Background To evaluate the efficacy of rituximab in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) patients not responding to conventional immune therapies. Methods An open-label, ...
Multiple Sclerosis News Today12d
T-cells help protect against risk of COVID-19 infection in MS: Study
MS patients on B-cell depleting therapies are still protected against COVID-19 risk due to greater anti-viral T-cell activity ...
hss.edu13d
IRB Number: 2018-2011
The main purpose of this randomized controlled clinical trial is to learn about the safety of the experimental treatment of SSc with the combination of rituximab, belimumab and background MMF. This ...
Pharmazeutische Zeitung13d
Update MS-Therapie
Sechs neue Arzneistoffe bereichern seit 2020 die Therapieoptionen bei Multipler Sklerose (MS). Auch sie greifen in das ...
Frontiers15d
Comparative Effectiveness of Rituximab and Common Induction Therapies for Lupus Nephritis: A Systematic Review and Network Meta-Analysis
Objective: This study aimed to compare the efficacy and safety (infection events) between rituximab (RTX), tacrolimus (TAC), mycophenolate mofetil (MMF), and cyclophosphamide (CYC) as induction ...
BMJ15d
Adjuvant rituximab, a potential treatment for the young patient with Graves’ hyperthyroidism (RiGD): study protocol for a single-arm, single-stage, phase II trial
New immunomodulatory agents are available and the anti-B cell monoclonal antibody rituximab is of particular interest because it targets cells that manufacture the antibodies that stimulate the ...
C&EN21d
Using Mass Spectrometry to Quantify Rituximab and Perform Individualized Immunoglobulin Phenotyping in ANCA-Associated Vasculitis
† Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota 55905, United States ‡ Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, Minnesota 55905, ...
The Lancet22d
Clinical trials for progressive multiple sclerosis: progress, new lessons learned, and remaining challenges
aQueen Square Multiple Sclerosis Centre, Department of Neuroinflammation, UCL Queen Square Institute of Neurology, Faculty of Brain Sciences, University College London, London, UK bMedical Research ...
rmdopen.bmj22d
Rituximab to treat prolidase deficiency due to a novel pathogenic copy number variation in PEPD
Introduction of rituximab (RTX) treatment in this patient led to sustained recession of mucocutaneous ulceration, enabling tapering of steroids. High interleukin-1β (IL-1β) production by this ...
The Lancet23d
2021 MAGNIMS–CMSC–NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis
dNeuroradiological Academic Unit, University College London Queen Square Institute of Neurology, University College London, London, UK eFaculty of Brain Sciences, University College London Queen ...